What is HC Wainwright’s Estimate for ENTA Q1 Earnings?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Enanta Pharmaceuticals in a report released on Tuesday, December 24th. HC Wainwright analyst E. Arce anticipates that the biotechnology company will post earnings per share of ($1.18) for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.45) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.54) EPS, FY2026 earnings at ($7.90) EPS, FY2027 earnings at ($8.00) EPS and FY2028 earnings at ($7.36) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The business’s revenue was down 22.8% on a year-over-year basis. During the same quarter last year, the firm posted ($1.33) EPS.

Other analysts have also issued reports about the company. Robert W. Baird lowered their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $6.01 on Friday. The company has a market cap of $127.38 million, a price-to-earnings ratio of -1.10 and a beta of 0.49. The stock has a fifty day moving average price of $9.15 and a two-hundred day moving average price of $11.49. Enanta Pharmaceuticals has a 52-week low of $5.70 and a 52-week high of $17.80.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new stake in Enanta Pharmaceuticals during the 2nd quarter worth $35,000. US Bancorp DE grew its stake in shares of Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 4,243 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter worth $122,000. Quest Partners LLC increased its holdings in Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares during the last quarter. Finally, Valence8 US LP acquired a new position in Enanta Pharmaceuticals in the third quarter valued at about $207,000. 94.99% of the stock is owned by institutional investors.

Insider Activity at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 13.64% of the stock is owned by company insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.